David-Alexandre C. Gros

David-Alexandre C.
Gros was the founder of Imbria Pharmaceuticals, Inc. founded in 2018, where he held the title of Chairman & Chief Executive Officer.
He is also the founder of Eliem Therapeutics, Inc. Dr. Gros's current job is as Chief Executive Officer & Director at Eledon Pharmaceuticals, Inc. where he started in 2020.
Dr. Gros's former jobs include President, Chief Operating & Financial Officer at Neurocrine Biosciences, Inc. in 2017, Chief Strategy Officer & Executive Vice President at Sanofi from 2013 to 2015, Associate Principal at McKinsey & Co., Inc. from 2002 to 2006, Member-Supervisory Board at Saint Jean Groupe SA, Chief Financial Officer at Alnylam Pharmaceuticals, Inc. from 2016 to 2017, and Principal at Centerview Partners LLC from 2009 to 2011.
He also held the title of Chief Strategy Officer at Sanofi SA. Dr. Gros's education history includes an undergraduate degree from Dartmouth College in 1995, an MBA degree from Harvard Business School in 2002, and a doctorate degree from The Johns Hopkins University School of Medicine in 1999.